Free Trial
LON:DDDD

4D pharma (DDDD) Share Price, News & Analysis

4D pharma logo
GBX 16.66
0.00 (0.00%)
(As of 11/8/2022)

About 4D pharma Stock (LON:DDDD)

Key Stats

Today's Range
16.66
16.66
50-Day Range
16.66
16.66
52-Week Range
16.66
16.66
Volume
1.21 million shs
Average Volume
2.96 million shs
Market Capitalization
£30.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Receive DDDD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

DDDD Stock News Headlines

Barclays Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)
Stop whatever you’re doing!
This next step in your trading career is a simple, yet important one. I want you to take 1 minute to sign up for FREE algo alerts powered by StocksToTrade.
4D Molecular Therapeutics (FDMT) Receives a Buy from RBC Capital
See More Headlines

DDDD Stock Analysis - Frequently Asked Questions

4D pharma's stock was trading at GBX 16.66 at the start of the year. Since then, DDDD shares have increased by 0.0% and is now trading at GBX 16.66.
View the best growth stocks for 2024 here
.

4D pharma plc (LON:DDDD) posted its earnings results on Wednesday, September, 30th. The company reported ($14.06) earnings per share for the quarter.

Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that 4D pharma investors own include Omega Diagnostics Group (ODX), Tullow Oil (TLW), B&M European Value Retail (BME), BP (BP), Coats Group (COA), genedrive (GDR) and Greencore Group (GNC).

Company Calendar

Last Earnings
9/30/2020
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
106
Year Founded
N/A

Profitability

Net Income
£-31,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£718,000.00
Cash Flow
GBX 11.60 per share
Book Value
GBX 18 per share

Miscellaneous

Free Float
N/A
Market Cap
£30.04 million
Optionable
Not Optionable
Beta
2.63
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (LON:DDDD) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners